Cohort1: dose level 1_NHL
|
Administration route |
infusion |
Dosage |
0.5~8E6 cells/kg |
Donor type |
Autologous|Allogeneic |
Pts |
87 |
Age |
Child, Adult, Older_Adult |
Lymph depletion |
Yes |
Outcome |
61/87(CR); 7/87(PR) |
Adverse reactions |
9/87(cytokine release syndrome); 2/87(CAR T cell-related encephalopathy syndrome) |
References |
PMID:
34272481
|
|
Cohort2: dose level 2_NHL
|
Administration route |
infusion |
Dosage |
1~8E6 cells/kg |
Donor type |
Autologous|Allogeneic |
Pts |
28 |
Age |
Child, Adult, Older_Adult |
Lymph depletion |
Yes |
Outcome |
20/28(CR); 2/28(PR); 10/28(PD) |
Adverse reactions |
4/28(cytokine release syndrome) |
References |
PMID:
34272481
|
|
Cohort3: DLBCL
|
Administration route |
infusion |
Donor type |
Autologous|Allogeneic |
Pts |
56 |
Age |
Child, Adult, Older_Adult |
Lymph depletion |
Yes |
Outcome |
40/56(CR); 5/56(PR); 11/56(PD) |
References |
PMID:
34272481
|
|